Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00167362 · ClinicalTrials.gov registry record · Phase 3
Cognitive Enhancement Therapy for Early-Stage Schizophrenia
A Phase 3 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 67
- Enrollment target
NCT00167362 is a Phase 3 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 67 participants.
The verdict
NCT00167362, a Phase 3 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 67 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of cognitive enhancement therapy (CET) in treating cognitive abnormalities in people experiencing the early stages of schizophrenia.
Interventions
- BEHAVIORAL Cognitive enhancement therapy (CET)
- BEHAVIORAL Enriched supportive therapy (EST)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2001-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00167362
The ClinicalTrials.gov registry entry for NCT00167362 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cognitive enhancement therapy (CET) is the first listed.
NCT00167362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00167362 about?
NCT00167362 is a clinical study titled "Cognitive Enhancement Therapy for Early-Stage Schizophrenia". This study will determine the effectiveness of cognitive enhancement therapy (CET) in treating cognitive abnormalities in people experiencing the early stages of schizophrenia.
What is the current status of trial NCT00167362?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 67 participants. The study started on 2001-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00167362?
The interventions under investigation include: Cognitive enhancement therapy (CET) (BEHAVIORAL), Enriched supportive therapy (EST) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00167362?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.